p55 Tumour necrosis factor receptor in bone marrow-derived cells promotes atherosclerosis development in low-density lipoprotein receptor knock-out mice

Cardiovascular Research

Volumn 80, Issue 2, 2008, Pages 309-318

  Xanthoulea, Sofia ^a   Gijbels, Marion J J ^a   Van Der Made, Ingeborg ^a   Mujčić, Hilda ^a   Thelen, Melanie ^a   Vergouwe, Monique N ^a   Ambagts, Matheus H C ^b   Hofker, Marten H ^a,c   De Winther, Menno P J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atherosclerosis; Cytokines; Inflammation; Leukocytes; Macrophages

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P55; RNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; GENOTYPE; HEART; HISTOLOGY; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNOCKOUT MOUSE; LEUKOCYTE; LIPID DIET; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; ATHEROSCLEROSIS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; ENDOCYTOSIS; FOAM CELLS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LIPID METABOLISM; LIVER; MICE; MICE, INBRED C57BL; RECEPTORS, LDL; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SCAVENGER RECEPTORS, CLASS A; TIME FACTORS;

EID: 54149098458     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn193     Document Type: Article

References (29)

1. Schreyer SA, Vick CM, LeBoeuf RC. Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem 2002;277:12364-12368.
2. Niemann-Jonsson A, Dimayuga P, Jovinge S, Calara F, Ares MP, Fredrikson GN et al. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-alpha expression. Arterioscler Thromb Vasc Biol 2000;20:2205-2211.
3. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317-2322.
4. Bruunsgaard H, Skinhoj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol 2000;121:255-260.
5. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-2153.
6. Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002;23:376-383.
7. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
8. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995;5:392-399.
9. Canault M, Peiretti F, Mueller C, Kopp F, Morange P, Rihs S et al. Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis 2004;172:211-218.
10. Boesten LS, Zadelaar AS, van Nieuwkoop A, Gijbels MJ, de Winther MP, Havekes LM et al. Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-leiden transgenic mice. Cardiovasc Res 2005;66:179-185.
11. Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005;180:11-17.
12. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004;24:2137-2142.
13. Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem 1996;271:26174-26178.
14. Blessing E, Bea F, Kuo CC, Campbell LA, Chesebro B, Rosenfeld ME. Lesion progression and plaque composition are not altered in older apoE-/- mice lacking tumor necrosis factor-alpha receptor p55. Atherosclerosis 2004;176:227-232.
15. Chandrasekharan UM, Mavrakis L, Bonfield TL, Smith JD, DiCorleto PE. Decreased atherosclerosis in mice deficient in tumor necrosis factor-alpha receptor-II (p75). Arterioscler Thromb Vasc Biol 2007;27:e16-e17.
16. Zhang L, Peppel K, Sivashanmugam P, Orman ES, Brian L, Exum ST et al. Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:1087-1094.
17. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-467.
18. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92:883-893.
19. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, Fijneman RJ et al. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003;112:1176-1185.
20. Rebel VI, Hartnett S, Hill GR, Lazo-Kallanian SB, Ferrara JL, Sieff CA. Essential role for the p55 tumor necrosis factor receptor in regulating hematopoiesis at a stem cell level. J Exp Med 1999;190:1493-1504.
21. Kollias G, Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002;13:315-321.
22. Li H, Freeman MW, Libby P. Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. J Clin Invest 1995;95:122-133.
23. Hsu HY, Nicholson AC, Hajjar DP. Inhibition of macrophage scavenger receptor activity by tumor necrosis factor-alpha is transcriptionally and post-transcriptionally regulated. J Biol Chem 1996;271:7767-7773.
24. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-281.
25. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-897.
26. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol 1990;136:1229-1233.
27. Xanthoulea S, Curfs DM, Hofker MH, de Winther MP. Nuclear factor kappaB signaling in macrophage function and atherogenesis. Curr Opin Lipidol 2005;16:536-542.
28. Dixon WG, Symmons DP. What effects might anti-TNF alpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF alpha in cardiovascular pathophysiology. Ann Rheum Dis 2007;66:1132-1136.
29. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 2004;50:1040-1050.